## Sources 1. [Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium](https://www.annualreviews.org/content/journals/10.1146/annurev-med-050224-104951?TRACK=RSS) 2. [Molecular Subtypes of Neuroendocrine Carcinoma: From Chaos to Consensus](https://www.annualreviews.org/content/journals/10.1146/annurev-pathmechdis-042524-023153?TRACK=RSS) 3. [The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious Diseases](https://www.annualreviews.org/content/journals/10.1146/annurev-pharmtox-071724-100739?TRACK=RSS) 4. [From Oil Spills to Air Pollution: The Emergence of Phenanthrene as a Ubiquitous Cardiac Toxicant](https://www.annualreviews.org/content/journals/10.1146/annurev-physiol-042224-093212?TRACK=RSS) --- ### From Oil Spills to Air Pollution: The Emergence of Phenanthrene as a Ubiquitous Cardiac Toxicant **Author:** Holly A. Shiels * **The Environmental Prevalence of PAHs:** Polycyclic aromatic hydrocarbons (PAHs) are widespread environmental pollutants released primarily through industrial processes and the incomplete combustion of organic matter [1]. Their persistence in the air, water, and soil allows them to accumulate and directly impact human, animal, and ecosystem health [1]. * **Specific Toxicity of Phenanthrene:** The review focuses on **phenanthrene, a 3-ringed PAH that has recently gained attention for its specific and potent cardiotoxic effects** [1]. This chemical can undergo transformations both in the environment and within the body, producing metabolites that further influence and disrupt heart function [1]. * **Mechanisms of Electrical Disruption:** Phenanthrene and its derivatives are shown to **alter the electrical activity of the heart, significantly increasing the probability of arrhythmias** [1]. This disruption occurs because the toxicant inhibits essential ion channels, specifically repolarizing currents (like $I_K$) and depolarizing currents (like $I_{Na}$ and $I_{Ca}$) [1]. * **Impact on Cardiac Contractility:** Beyond electrical disruptions, phenanthrene also directly damages the mechanical pumping ability of the heart [1]. It **reduces the amplitude of the intracellular calcium ($Ca^{2+}$) transient** across all examined species, which directly impairs cardiac contractility [1]. * **A Ubiquitous Threat Across Species:** The review comprehensively summarizes how phenanthrene modulates vertebrate cardiac function across highly diverse exposure routes, **ranging from fish exposed to crude oil spills in marine environments to humans inhaling polluted urban air** [1]. ### Molecular Subtypes of Neuroendocrine Carcinoma: From Chaos to Consensus **Authors:** Zhanyu Wang, Nan Sun, Jie He, Esther Redin, and Charles M. Rudin * **The Aggressive Nature of NECs:** Neuroendocrine carcinomas (NECs) are a family of notably aggressive and lethal malignancies that can arise in diverse anatomical sites throughout the body [2]. * **Evolution of Molecular Subtyping in SCLC:** Understanding of tumor heterogeneity in small cell lung cancer (SCLC) has significantly advanced through molecular subtyping based on key lineage-specifying transcription factors [2]. Historically, SCLC heterogeneity was defined by the presence of **ASCL1, NEUROD1, POU2F3, and YAP1** [2]. * **A Unified Pan-NEC Framework:** Recent studies have identified a fifth subtype driven by the lineage-specifying factor **HNF4A**, revealing that extrapulmonary NECs display heterogeneity analogous to SCLC [2]. The authors propose a unified "pan-NEC" classification framework—**the ANHPY subtypes**—which standardizes molecular subtyping across pulmonary, gastro-entero-pancreatic (GEP), and genitourinary systems [2]. * **Lineage Hallmarks and Clinical Connections:** The ANHPY framework outlines distinct lineage phenotypes, specifically neuroendocrine, neuronal, GEP-like, tuft-like, and epithelial–mesenchymal transition (EMT) phenotypes [2]. * **Key Takeaway for Precision Medicine:** By delineating these subtypes, the review successfully connects the biological lineage markers to specific genetic alterations, clinicopathological features, and, most importantly, **therapeutic vulnerabilities, providing a molecular roadmap for precise NEC research and clinical management** [2]. ### Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium **Authors:** Aman Kansal, Husam M. Salah, and Jennifer A. Rymer * **The "Hibernating Myocardium" Hypothesis:** Emerging in the 1970s, the concept of the hibernating myocardium posited that certain heart tissue becomes **chronically impaired but remains viable following ischemia, and that its function could be completely recovered if blood flow was restored via revascularization** [3]. * **Shifting Evidence from Clinical Trials:** While initial observational studies heavily supported the benefits of revascularization for this condition, later randomized controlled trials—such as PARR-2, HEART, and STICH—yielded mixed and highly debated results, with STICH showing mortality benefits only after a substantially extended follow-up period [3]. * **Advances in Medical Therapy:** Over the decades, remarkable advancements in optimal medical therapies have raised serious questions about the absolute necessity and added value of invasive revascularization procedures [3]. * **Disproving the Paradigm:** Recent landmark trials, specifically the **ISCHEMIA and REVIVED-BCIS2 trials, demonstrated that revascularization provides limited to no added benefit over optimal medical therapy** in stable patients [3]. * **Key Takeaway:** The accumulation of modern trial data has effectively challenged and disproved the 45-year-old foundational concept of the hibernating myocardium, suggesting that **medical management is often equally as effective as surgical intervention for stable ischemic cardiomyopathy** [3]. ### The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious Diseases **Authors:** Adeniyi Olagunju, Simone Perazzolo, Zachary R. Stephen, Mark Ryan, Xiaolin Xu, Prajith Venkatasubramanian, Shakir Atoyebi, Rachele Delle Fratte, Andrew Owen, Charles Flexner, and Rodney J.Y. Ho * **Bridging the Gap in Infectious Disease Treatment:** Long-acting (LA) therapeutics are rapidly becoming a cornerstone strategy for the treatment and prevention of infectious diseases, **driven by the urgent need to overcome adherence gaps and limitations associated with traditional short-acting, daily drug formulations** [4]. * **Focus on High-Burden Global Diseases:** The review assesses the current state of approved LA therapeutics and promising innovations currently in the development pipeline specifically targeting diseases with massive global burdens, including **HIV, hepatitis B and C, tuberculosis, malaria, and COVID-19** [4]. * **Innovative Development Approaches:** The authors highlight the use of advanced computational modeling as a vital tool to accelerate the development of LA therapeutics, particularly for vulnerable groups such as pediatric and perinatal populations [4]. The role of LA therapeutics as rapid countermeasures for future diseases with pandemic potential is also emphasized [4]. * **Barriers to Global Access:** Despite their promise, significant hurdles remain. **Complexities in manufacturing intricate LA formulations and the diversity of patent-protected technologies create severe barriers to global access** [4]. * **Strategic Framework for the Future:** To realize the full potential of LA therapeutics for global health, the authors propose a **multipronged strategic framework that explicitly includes accelerating equitable access through generic product manufacturing and upscaling** [4].